Scientifically Formulated with Ingredients for Urinary Urgency, Frequency and Leakage
LOS ANGELES, Calif., Oct. 4, 2023 /PRNewswire/ — O Positiv, the supplement brand breaking taboos in women’s health, introduces their newest product URO Bladder Control Capsules.
URO Bladder Control Capsules from Women’s Health Brand O Positiv
Since the launch of its debut product FLO, the first-ever PMS support supplement on the market, O Positiv’s mission is to prioritize and advocate for women with effective products to address health concerns that have been historically overlooked. By offering a range of products to address vaginal, digestive, urinary, menstrual and menopausal health and fostering a community for education and discussion, O Positiv has positioned itself as a premier women’s health brand.
URO Bladder Control, once again, tackles an issue that many women suffer from in silence. It helps to reduce occasional urinary leakage, to improve daytime and nighttime urinary frequency and to relieve the full bladder feeling. Its scientifically formulated ingredients support healthy bladder control and normal bladder function.
Co-found Brianna Bitton says, “We’ve listened to our community and heard countless stories from women who suffer from a decrease in bladder control as they age, whether it be losing sleep from frequent trips to the bathroom during the night or leakage after a good laugh. It doesn’t have to be this way. We want to actively advocate for women with our products.”
The Mayo Clinic reports that urine incontinence, or the involuntary leakage of urine, is a common symptom that affects 50% of adult women. Prevalence of this problem increases with age, as up to 75% of women over 65 report urine leakage.
Each URO Bladder Control supplement contains Pumpkin Seed Extract, a powerhouse ingredient rich in B vitamins, amino acids, iron and zinc, all known to improve structural support of the bladder, which helps normalize urinary control; Soy Germ Extract, a naturally powerful plant extract known to support healthy bladder function and help relieve occasional urinary distress when combined with pumpkin seed extract; and Saw Palmetto which has a long history of use for supporting healthy urinary function.
In a clinical study using the ingredients in URO Bladder Support, 90% of participants reported that daily supplementation was helpful at addressing their urinary bladder issues.
To further advocate for women’s health, O Positiv works with the global nonprofit Period to end period poverty and stigma through service, education and advocacy.
About O Positiv O Positiv is the health and wellness brand prioritizing women by creating effective products to address health concerns that have been historically overlooked. O Positiv aims to break taboos with a line of products to address vaginal, skin, digestive, menstrual and menopausal health. For more information, visit opositiv.com.
CAMBRIDGE, Mass., Oct. 4, 2023 /PRNewswire/ — Flare Therapeutics Inc., a biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, today announced a poster presentation highlighting an artificial intelligence-based model developed in partnership with PathAI that identifies the luminal subtype in Urothelial Carcinoma as a novel biomarker approach for its first-in-class clinical candidate FX-909 at the upcoming 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 11-15 in Boston, Massachusetts.
Details for the poster presentation are as follows:
Abstract Title: AI analysis of histological images accurately identifies luminal subtype urothelial carcinomas characterized by high PPARG expression Poster Number: B016 Presenter: Stefan Kirov, Vice President, Computational Biology, Flare Therapeutics Date/Time: Friday, October 13, 2023, from 12:30 to 4:00 p.m. ET Location: Exhibit Hall D, Hynes Convention Center, Boston
About Flare Therapeutics Inc. Flare Therapeutics is a biotechnology company exclusively focused on drugging transcription factors (TFs) to fully unlock the therapeutic potential of this previously elusive target class. Flare Therapeutics’ integrated discovery engine converges rich genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule ligands capable of modulating TFs of high therapeutic potential. Our proteomic and mass spectrometry platform is powered by a proprietary library of electrophilic compounds unique to Flare Therapeutics. The team has rapidly established an emerging pipeline of programs, highlighted by FX-909, a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced Urothelial Cancer that has entered the clinic. For more information, please visit www.flaretx.com and follow us on LinkedIn.
About FX-909 Flare Therapeutics’ lead investigational compound, FX-909, is a first-in-class novel, highly potent and selective small molecule that inhibits the transcription factor peroxisome proliferator-activated receptor gamma (PPARG) to treat patients with the luminal subtype of advanced urothelial carcinoma (UC). FX-909 is currently undergoing investigation in a Phase 1 clinical study, a first-in-human, dose-escalation and expansion study evaluating safety, tolerability, pharmacokinetics, pharmacodynamics and clinical activity. Preclinical data for FX-909 has demonstrated robust anti-tumor activity, excellent PK/PD correlation, durable efficacy, and a favorable safety profile in mouse models of UC (PPARG-amp and RXRA-mut) at very low oral doses.
About Advanced Urothelial Carcinoma (UC) In 2020, there were an estimated 725,549 people living with bladder cancer in the United States alone, making it the sixth most common cancer overall, and fourth most common among men (SEER – 2020). Each year, there are more than 83,000 new cases diagnosed among men and women, and about 25% of those cases are classified as muscle-invasive UC (DRG 2020). Advanced UC has high rates of recurrence, where treatment outcomes have remained poor with typical five-year survival rates of 8% in advanced metastatic disease (SEER – 2020). The transcription factor peroxisome proliferator-activated receptor gamma (PPARG) is associated with the luminal lineage subtype reflecting approximately 65% of all advanced UC cases (Robertson, Cell 2017). Recurrent genetic alterations in PPARG are characteristic of this molecular subtype.
WASHINGTON, Oct. 4, 2023 /PRNewswire/ — Rapidan Energy Group, a leading energy market, policy, and geopolitical consulting firm, is proud to announce the addition of Linda Giesecke as Director of Refined Products, marking Rapidan’s expansion into the global refining market.
A seasoned professional with two decades of experience in global oil markets, Linda’s expertise further strengthens Rapidan’s commitment to providing industry-leading energy research products to its global clientele.
Linda joins Rapidan from ESAI Energy, where she served as Director – Head of Demand Analysis. In her role at ESAI Energy, Linda led a number of global programs and initiatives, including product analysis of ESAI’s monthly Global Fuels report, fuel market and light vehicle outlooks, analysis of energy transition technologies and regulations, and ESAI’s monthly Europe Watch report.
Linda previously held several roles at Wood Mackenzie, where she led the oil team’s global oil demand analysis, became a key contributor to the company’s Macro Oils analysis, and developed long-term models of transportation fuels and vehicle fleets. Prior to Wood Mackenzie, Linda was an Oil Market Analyst at ESAI and served as a Senior Analyst with Cambridge Economics.
Linda’s appointment comes at a pivotal moment in Rapidan’s expansion into the global refined products market. “We are delighted to have Linda join our team of veteran energy market experts,” said Bob McNally, Founder and President of Rapidan Energy Group. “Linda’s deep understanding of the fuels, refined products, and energy transition markets, coupled with her experience in global oil forecasting, will add invaluable expertise to our team as we expand our service offerings.”
Linda holds a BA in Economics from Lafayette College and a Diplom in Economics from the University of Mannheim, Germany. She is based in the greater Boston area.
About Rapidan
Rapidan Energy Group provides differentiated and actionable insights on energy markets, policy, and geopolitics. We help leading corporations and financial firms identify opportunities and manage risks in the global energy industry and markets.
ATLANTA, Oct. 4, 2023 /PRNewswire/ — The U. S. Food and Drug Administration (FDA) has awarded Lipogems another Investigational Device Exemption (IDE) study for the use of MicroFat for the treatment of knee osteoarthritis (OA). The second IDE Study will be conducted for the safety and efficacy for the treatment of knee OA compared to saline and will include 15-20 well-respected academic and private practice orthopaedic institutions.
Dr. Brandon Broome, orthopaedic surgeon, performs Lipogems procedure
Lipogems has been used in more than 60,000 procedures worldwide, is supported by 140+ peer-reviewed publications, and is currently FDA cleared for use in general applications in orthopaedics, arthroscopy, and nine other specialties since 2014. Lipogems has worked closely with the FDA to seek a separate FDA clearance for a specific indication in knee OA and while Lipogems pursues the Knee OA indication physicians may continue to use the product for the general indications specified in the existing FDA clearance.
Carl Llewellyn, CEO of Lipogems USA, stated “We are thrilled to announce another milestone in our pursuit for specific indication in knee osteoarthritis. The enrollment in our first study comparing MicroFat vs corticosteroid has been impressive and we see this momentum carrying into the saline study. The completion of both IDE Studies in knee OA and anticipated approval will permit Lipogems to educate directly to physicians and millions of consumers that have tried conservative options but are not ready or do not qualify for a total knee replacement. We pursued this specific indication because over 40+ independent peer-reviewed publications with up to 5 years follow up showed extremely positive results using MicroFat for Knee OA.”
About Lipogems
Lipogems is a privately held medical device company that uses adipose tissue solutions to help maintain or restore patient lifestyles and to improve quality of life and recovery times. Lipogems’ products are used in a diverse range of areas, including plastic and reconstructive surgery, orthopaedics, general surgery, exploring products for wound care and more. Lipogems is available in 29 countries and the aim is getting patients back to their lives through our global reach and scientific excellence. Information about Lipogems can be found on: http://www.understandinglipogems.com/
MADISON, Wis., Oct. 4, 2023 /PRNewswire/ — SVA is excited to begin our celebration of 50 years in business, culminating with our official anniversary in 2024. For half a century, SVA has been the backbone of success for countless businesses and individuals spanning the Midwest and beyond.
Founded in Madison, WI, in 1974 by Terry Von Haden and John Suby, SVA began as Suby, Von Haden & Associates, S.C., Certified Public Accountants. SVA has grown throughout the past 50 years to encompass SVA Certified Public Accountants, SVA Consulting, and SVA Life Sciences. Our humble origins keep us grounded, while our expertise and approach have made us the preferred professional services firm for a diverse range of clients.
Serving people better over the last 50 years has instilled us with wisdom, resilience, and adaptability, but our vision for the future is what truly invigorates us. From the fundamentals that define our ethos to our unwavering commitment to community and excellence, our aspirations go beyond serving. We’re meticulously crafting the future, ensuring that the next half-century is as transformative as the last.
“Our history is rich in lessons of perseverance, adaptability, and innovation, all rooted in our core values to Serve People Better,” says CEO Matt Vanderloo. “As we mark our 50-year milestone since our inception in 1974, I’m amazed at our journey. I’m genuinely thrilled for what the future holds for SVA as we continue our pursuit to becoming a more than 100-year-old firm.”
Serve People Better
The core of what makes us SVA is our promise to Serve People Better. These three words describe how we work with our clients, our partners, and each other. It is who we are and what drives our success.
Our very DNA is structured by 31 Fundamentals – principles that define our unique culture and direct our every move. These principles guide and influence us when we connect with clients, partners, and each other. They embody SVA’s essence and fuel our continual growth and success.
Recognizing Excellence
As we reflect on our past, embrace the present, and pave the way for the future, SVA continues to earn recognition for our unwavering commitment to excellence. We have been certified as a Great Place to Work® for six years in a row, and have also been named as one of Inside Public Accounting’s Top Firms and a 2023 Regional Leader in Accounting Today. In addition, SVA is part of the Acumatica President’s Club, an Avnet Cloud Partner of the Year, and has earned Veeva Services Partner certification for three years in a row.
Our mission is simple: to provide business owners and executives with unmatched financial and technology solutions to meet their challenges, capitalize on their opportunities, and balance their risk and reward. We strive to continue to meet our clients’ needs for the next 50 years, and beyond.
Engage with SVA’s Legacy
As SVA looks forward to another half-century of unparalleled service and commitment, we invite media representatives, clients, partners, and the broader community to join us in our celebrations and milestones. For further information, inquiries, or interview opportunities, please contact Patrick Ryan at 608-826-2363, or via email at [email protected]. For more details, visit our website at https://www.sva.com/50th-anniversary. Here’s to the future and to continued excellence in serving people better.
The Double Good Kids Foundation hosts full day of hands-on, educational and sensory-friendly experiences for children with special needs
CHICAGO, Oct. 4, 2023 /PRNewswire/ — The Double Good Kids Foundation, a non-profit organization dedicated to tilting the playing field and creating joy for children with special needs, held its first ever Double Good Days event at the Kohl Children’s Museum in Glenview, Ill. on Sunday, Oct. 1. The event brought together 550 attendees from across the Chicagoland area, along with a variety of local non-profit organizations, for a day filled with equitable learning experiences and activities. Photos of the event can be found HERE.
The event held two separate sessions to ensure as many families as possible could attend without overwhelming the children. Event partners from the Chicago area included GiGi’s Playhouse, Ignite Glass Studios, Jack and Jill of America, Lincolnway Special Recreation Association, Mane in Heaven Mini Therapy Horses, Rainbow Animal Assisted Therapy, Science Olympiad and USASF Exceptional Athletes.
“We are thrilled with the turnout of the first Double Good Days event, but are even more proud to have had the opportunity to connect with these families,” said Tim Heitmann, founder and CEO of Double Good. “We’re very grateful to be able to provide these experiences to children with special needs and their families – a community who is often underrepresented – and know it could not have been accomplished without the support of our Double Good customers and the participating organizations that helped bring it to life.”
Since 2017, Double Good has been in the business of supporting qualified and impactful non-profit organizations across the U.S. through the donation of popcorn, equipment, educational opportunities and volunteer hours. That history, paired with the desire to maximize our impact on the lives of children with special needs, led to the creation of the foundation.
“Thanks to the wonderful people at the Double Good Kids Foundation for organizing such a great event for our kids. Each activity was new and fun for my son – he especially loved the therapy dogs and the Paint-a-Car. We can’t wait for next year,” said Danielle M., one of the parents in attendance at Double Good Days.
The Double Good Kids Foundation acts as an extension of the Double Good mission, focusing specifically on reaching an underrepresented segment of America’s youth and bringing them joy through fun-filled, interactive, sensory experiences.
For more information on Double Good and the Double Good Kids Foundation, visit www.doublegood.com.
About Double Good Founded in 1998, Double Good was born out of a love for delicious popcorn and grew into a passion for positively impacting the community. Double Good combines an easy-to-use virtual fundraising platform with award-winning popcorn to help create opportunities for children and teens to realize their dreams. Most recently, Double Good was included in the Inc. 5000 list of fastest-growing businesses for 2023 and was recognized on the Crain’s Fast 50 list (No. 18) for Chicago’s fastest growing companies. In 2022, Double Good was also honored with Inc.’s Best in Business award for its popcorn donation program, which has enabled users to donate millions of dollars worth of popcorn to health care workers and youth advocates across the country. In addition to its fundraising platform and donation program, the company amplifies inspiring stories and social issues facing today’s youth through its content production arm, Double Good Studios, and the Double Good Kids Foundation dedicated to providing equitable experiences for children with special needs. To learn more on how Double Good can create joy for you, visit www.doublegood.com.
About The Double Good Kids Foundation The Double Good Kids Foundation is a 501(c)(3) organization dedicated to tilting the playing field for children with special needs and unlocking experiences they may not be able to access. The Double Good Kids Foundation acts as an extension of Double Good’s mission, reaching an underrepresented segment of America’s youth and bringing them joy through fun-filled, interactive, sensory-friendly experiences. For more information on the Double Good Kids Foundation, or to learn more about Double Good, visit www.doublegood.com/shop.
